客服热线:18202992950

Stabilised mRNA with increased G/C-content and optimised codon usage for gene therapy 发明申请

2023-06-30 3070 1885K 0

专利信息

申请日期 2025-06-24 申请号 EP07002195
公开(公告)号 EP1832603A2 公开(公告)日 2007-09-12
公开国别 EP 申请人省市代码 全国
申请人 CureVac GmbH
简介 Pharmaceutical composition (A) contains at least one modified mRNA (I) encoding a biologically active or antigenic (poly)peptide (II), plus a carrier and/or vehicle. Pharmaceutical composition (A) contains at least one modified mRNA (I) encoding a biologically active or antigenic (poly)peptide (II), plus a carrier and/or vehicle. (I) has, in the (II)-coding region : (i) a G/C content higher than that for the wild-type RNA; and/or (ii) at least one codon in the wild-type sequence, for which the tRNA is rare, is replaced by a codon, representing the same amino acid, for which the tRNA is common, but the amino acid sequence encoded by the modified mRNA is the same as that encoded by the wild type. ACTIVITY : Cytostatic; Virucide; Antibacterial; Protozoacide; Nootropic; Neuroprotective; Antiparkinsonian; Immunostimulant. No details of tests for any of these activities are given. MECHANISM OF ACTION : Gene Therapy; Vaccine. No biological data given.


您还没有登录,请登录后查看下载地址


反对 0举报 0 收藏 0 打赏 0评论 0
下载排行
网站首页  |  关于我们  |  联系方式  |  使用协议  |  版权隐私  |  网站地图  |  排名推广  |  广告服务  |  积分换礼  |  网站留言  |  RSS订阅  |  违规举报  |  京ICP备2021025988号-4